Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2026 16:35 ET | Source: AIM ImmunoTech Inc.

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on...
February 12, 2026 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer ...
February 12, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
February 12, 2026 07:30 ET | Source: EDAP TMS S.A.

EDAP Announces Appointment of David Horn to Board of Directors

EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) (“the Company” or “EDAP”), a global leader in therapeutic...
February 11, 2026 08:30 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Commencement of Rights Offering

OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...
February 11, 2026 03:30 ET | Source: Custom Market Insights

[Latest] Global Cell Therapy Raw Materials Market Size/Share Worth USD 29.3 Billion by 2035 at a 18.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cell Therapy Raw Materials Market Size, Trends and Insights By Product (Media,...
February 06, 2026 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Live video webcast on Wednesday, February 11th at 1:40 PM EST OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today that it will...
February 05, 2026 09:26 ET | Source: Equity Insider

The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad...
February 05, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

As we advance toward human trials, we remain committed to delivering hope to patients facing limited options for aggressive cancers from solid tumors.
February 05, 2026 08:40 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

OCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive data in a year-end update from the ongoing Phase 2 clinical...